CL2021002992A1 - Métodos y composiciones que comprenden variantes de la proteína a de estafilococos (spa) - Google Patents

Métodos y composiciones que comprenden variantes de la proteína a de estafilococos (spa)

Info

Publication number
CL2021002992A1
CL2021002992A1 CL2021002992A CL2021002992A CL2021002992A1 CL 2021002992 A1 CL2021002992 A1 CL 2021002992A1 CL 2021002992 A CL2021002992 A CL 2021002992A CL 2021002992 A CL2021002992 A CL 2021002992A CL 2021002992 A1 CL2021002992 A1 CL 2021002992A1
Authority
CL
Chile
Prior art keywords
spa
compositions
methods
variants
staphylococcal protein
Prior art date
Application number
CL2021002992A
Other languages
English (en)
Inventor
Olaf Schneewind
Dominique Missiakas
Yan Sun
Hwan Keun Kim
Miaomiao Shi
Xinhai Chen
Original Assignee
Univ Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Chicago filed Critical Univ Chicago
Publication of CL2021002992A1 publication Critical patent/CL2021002992A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Las realizaciones se refieren a métodos y composiciones para prevenir o tratar una infección bacteriana, particularmente la infección por una bacteria Estafilococo. Las realizaciones se refieren a una variante mejorada de la Proteína A no toxigénica (SpA).
CL2021002992A 2019-05-14 2021-11-12 Métodos y composiciones que comprenden variantes de la proteína a de estafilococos (spa) CL2021002992A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962847832P 2019-05-14 2019-05-14

Publications (1)

Publication Number Publication Date
CL2021002992A1 true CL2021002992A1 (es) 2022-07-08

Family

ID=73288805

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002992A CL2021002992A1 (es) 2019-05-14 2021-11-12 Métodos y composiciones que comprenden variantes de la proteína a de estafilococos (spa)

Country Status (14)

Country Link
US (1) US20220323563A1 (es)
EP (1) EP3969031A4 (es)
JP (1) JP2022533096A (es)
KR (1) KR20220025724A (es)
CN (1) CN114340652A (es)
AU (1) AU2020273471A1 (es)
BR (1) BR112021022902A2 (es)
CA (1) CA3139981A1 (es)
CL (1) CL2021002992A1 (es)
CO (1) CO2021015337A2 (es)
IL (1) IL288060A (es)
MX (1) MX2021013833A (es)
SG (1) SG11202112479UA (es)
WO (1) WO2020232471A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114315996B (zh) * 2021-12-31 2023-01-17 博格隆(浙江)生物技术有限公司 一种重组ProteinA蛋白及亲和层析介质的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102844432A (zh) * 2010-03-24 2012-12-26 株式会社钟化 特异性结合免疫球蛋白的蛋白质以及免疫球蛋白结合性亲和配体
CA2803298C (en) * 2010-07-02 2020-07-14 The University Of Chicago Compositions and methods related to protein a (spa) variants
EP2690173B1 (en) * 2011-03-25 2019-07-03 Kaneka Corporation Protein for affinity-separation matrix
WO2014179744A1 (en) * 2013-05-03 2014-11-06 The University Of Chicago Staphylococcus live cell vaccines
CA2978847A1 (en) * 2015-04-17 2016-10-20 Arsanis Biosciences Gmbh Antibody directed against immunoglobulin-binding proteins of s. aureus

Also Published As

Publication number Publication date
CA3139981A1 (en) 2020-11-19
JP2022533096A (ja) 2022-07-21
EP3969031A4 (en) 2023-10-25
SG11202112479UA (en) 2021-12-30
BR112021022902A2 (pt) 2022-01-25
US20220323563A1 (en) 2022-10-13
AU2020273471A1 (en) 2021-12-23
WO2020232471A2 (en) 2020-11-19
WO2020232471A3 (en) 2020-12-30
CO2021015337A2 (es) 2022-02-17
KR20220025724A (ko) 2022-03-03
IL288060A (en) 2022-01-01
CN114340652A (zh) 2022-04-12
EP3969031A2 (en) 2022-03-23
MX2021013833A (es) 2022-03-17

Similar Documents

Publication Publication Date Title
MX2022006525A (es) Activo de polipeptidos de lisina contra bacterias gram-negativas.
CL2017002176A1 (es) Identificación bacteriana y prueba de susceptibilidad antimicrobiana.
ECSP20084373A (es) Tiofencarboxamidas sustituidas y análogos de las mismas
MX2019002978A (es) Composiciones que comprenden una bacteria no patogena y metodos para proteger plantas y animales anfitriones contra enfermedades micoticas, bacterianas y virales.
CO2019002624A2 (es) Compuestos antibióticos
MXPA05009352A (es) Metodos y composiciones para tratamiento y prevencion de staphylococcus y otras infecciones bacterianas.
TW201613575A (en) Treatment of polybacterial infections
NI202100018A (es) Moduladores de la expresión de pnpla3
ZA202002093B (en) Antibacterial compounds
MX2017012073A (es) Compuestos de minociclina para biodefensas.
ZA202006612B (en) Antibacterial compounds
NI202000085A (es) Moduladores de la expresión de apol1
MX2017009094A (es) Derivado de polimixina y usos del mismo.
CL2017001276A1 (es) Derivados de benzotiazol antibacterianos
BR112019024549A2 (pt) compostos derivados de glicopeptídeo e usos dos mesmos
CL2021002992A1 (es) Métodos y composiciones que comprenden variantes de la proteína a de estafilococos (spa)
CL2019000857A1 (es) Compuestos heterocíclicos y su uso para prevenir o tratar las infecciones bacterianas.
PL425327A1 (pl) Zastosowanie α,β,2',3'-tetrahydroksantohumolu
WO2018140707A8 (en) Synergistic combination of thermolysin and an antibacterial agent to reduce or eliminate bacterial biofilms from surfaces
WO2019079089A3 (en) Method to treat antimicrobial resistant candida
BR112017022796A2 (pt) composições antibacterianas e métodos
WO2018083314A3 (en) Use of phenothiazine derivative in the treatment of infectious purpura or purpura fulminans
MD3468957T2 (ro) Formă cristalină a (R)-4-(5-(ciclopropiletinil)izoxazol-3-il)-N-hidroxi-2-metil-2-(metilsulfonil)butanamidei în calitate de agent antibacterian
PL425328A1 (pl) Zastosowanie α,β-dihydroksantohumolu
AR114152A1 (es) Tratamiento antibacterial con cannabinoides